LPL Financial Welcomes Flood Financial Services
Get Alerts LPLA Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 1.8%
EPS Growth %: +18.8%
Join SI Premium – FREE
CHARLOTTE, N.C., June 14, 2018 (GLOBE NEWSWIRE) -- LPL Financial (NASDAQ: LPLA), a leading retail investment advisory firm and independent broker-dealer, today announced that Flood Financial Services has joined LPL’s broker/dealer and registered investment advisor (RIA) platforms. Flood Financial Services reported that, based on prior business*, it served approximately $330 million of client brokerage and advisory assets, as of June 1. For more information on the team’s move, visit LPL.com.
About LPL Financial LPL Financial is a leader in the retail financial advice market and the nation’s largest independent broker-dealer**. We serve independent financial advisors and financial institutions, providing them with the technology, research, clearing and compliance services, and practice management programs they need to create and grow thriving practices. LPL enables them to provide objective guidance to millions of American families seeking wealth management, retirement planning, financial planning and asset management solutions. LPL.com
Connect with Us!
https://www.linkedin.com/company/lpl-financial
https://www.facebook.com/LPLFinancialLLC
https://www.youtube.com/user/lplfinancialllc
Securities and Advisory Services offered through LPL Financial. A registered investment advisor, Member FINRA/SIPC.
*Asset numbers reported are based on prior business and have not been independently and fully verified by LPL Financial.
**Based on total revenues, Financial Planning magazine June 1996-2018
Media Contact:Lauren Hoyt-Williams980-321-1232[email protected]
Source: LPL Financial Holdings, Inc.Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Optro Accelerates Global Growth with Singapore Hub, Delivering Agentic GRC to APAC Enterprises
- Faraday Future Founder and Global CEO YT Jia Shares Weekly Investor Update: Provides Updates on Positive June Sales Targets; Recaps June 16 Robotics and Education Ecosystem Product Launch; Previews Ju
- Innovent Biologics Announces First Patient Dosed in a Phase 3 Clinical Trial of IBI3003(GPRC5D/BCMA/CD3 Tri-specific Antibody) for the Treatment of Multiple Myeloma
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share